Prof. Dr. Andreas Zaby

Deputy President
Department of Business and Economics
Professor for International Management
Specialist area: International Management

T: +49 (0)30 30877-1003
F: +49 (0)30 30877-1009
E: andreas.zaby(at)

Visitor's address
Schöneberg Campus
Building A
Room 2.37
Badensche Straße 52
10825 Berlin

Postal address
Hochschule für Wirtschaft und Recht Berlin
Schöneberg Campus
Badensche Straße 52
10825 Berlin


Academic and Professional Career

  • Since 1 April 2014 Deputy President of the Berlin School of Economics and Law (BSEL)
  • Since 2012: Member of the Advisory Board for Development Cooperation of the Senator for Economics, Technology and Research
  • 2010–2014: Vice President of the Berlin School of Economics and Law (BSEL)
  • 2009/10: Dean of studies at the Institute of Management Berlin (IMB)
  • Since 2008: Professor of International Management, BSEL
  • 2000-2008: Chief Financial Officer, biopharmaceutical company, Munich and Chapel Hill, USA
  • 1998-2000: Management consultant at Bain & Company, Munich and Zurich
  • 1994-1998: Research assistant at the Friedrich-Schiller-University, Jena
  • 1989-1994: Student of Business Administration in Bayreuth and San Diego, California

Key Aspects of practise

  • Venture capital financing
  • Mergers & acquisitions as well as licensing in the pharmaceutical industry
  • Management of high-tech companies, particularly bio-tech companies


  • Scholarship award from the Hanns Seidel Foundation, Munich
  • Finalist in the “Doctoral Thesis Competition” of the European International Business Academy, Stockholm
  • Winner of the Business Plan Competition of the Deutsche Ausgleichsbank, Bonn
  • Invited to join the “Beta Gamma Sigma” Honor Society for AACSB -accredited business schools

Key Aspects in Teaching

  • International & Strategic Management
  • Entrepreneurial finance
  • Innovation & Technology Management

Research Projects and Fields

  • Management of high-tech companies, particularly bio-tech companies
  • Venture capital and entrepreneurial finance
  • Economic incentives for the development of medicines for rare diseases (“orphan drugs”)

Selected, current Publications

  • Cooke, B. & Zaby, A. (2015) Skill gaps in business education: fulfilling the needs of tech startups in Berlin, in: Journal of Higher Education Theory and Practice, 15 (4), pp. 97-112.
  • Dietz, B. & Zaby, A. (2015) Strategic decisions under the EU regulatory framework for orphan drugs, in: Glowik, M. & Smyczek, S. (eds.), Healthcare – market dynamics, policies and strategies in Europe, Walter de Gruyter, Berlin/Boston.
  • Dietz, B., Zaby, A. & Bochert, K. (2015). Entwicklung und Vermarktung von Orphan Drugs. In: Die Pharmazeutische Industrie, 77 (4), S.462-467.
  • Dietz, B. & Zaby, A. (2014). Beteiligung von Biotechnologie-Unternehmen an der Entwicklung und Zulassung von Orphan Drugs – eine Analyse der Anreizmechanismen. In: Market Access & Health Policy, H. 6/2014. S. 24-27.
  • Zaby, A. (2013) Regional integration and innovation policy: ten years of experience with the EU-framework on stimulating innovation for treating rare diseases, in: Hemon, J. (ed.), Les integrations régionales: une approche comparative, Octarès Éditions, Toulouse.
  • Dörrenbächer, Ch./Zaby, A. (2013) Post- acquisition resource redeployment and synergy creation - the case of Heineken’s large acquisitions Scottish & Newcastle and FEMSA, in: Gammelgaard, J., Dörrenbächer, Ch. (eds.), The Global Brewery Industry - Markets, Strategies, and Rivalries, Edwin Elgar Publishing, Cheltenham.
  • Zaby, A. (2012) Venture capital after the crisis - strategies for managing risk with a special focus on life science, in: Financial Markets of Russia and Europe: Strategies of Post-crisis Development, Proceedings of the International Scientific Conference. Edition of St. Petersburg State University of Economics and Finance.
  • Zaby, A. (2011) Orphan Drugs: ten years of experience with the EU-framework on stimulating innovation for treating rare diseases, International Journal of Innovation, Policy and Management, 11 (3/4), pp. 291-306.
  • Heitmann, M./Knyphausen-Aufseß zu, D./Mansel, R./Zaby, A. (2011) Auf der Suche nach Einflussfaktoren auf die Wahl des Geschäftsmodells – Das Beispiel der Biotech-Industrie, in: Bieger, T., Knyphausen-Aufseß zu, D., Krys, Ch. (eds.), Innovative Geschäftsmodelle – konzeptionelle Grundlagen, Gestaltungsfelder und unternehmerische Praxis,, Springer-Verlag, Heidelberg.
  • Patzelt, H./Zaby, A./Knyphausen-Aufseß, D. zu (2006) Crisis management in entrepreneurial biotechnology companies, International Journal of Biotechnology, 8, pp. 244-264.
  • Knyphausen-Aufseß, D. zu/Zaby, A./Kind, S. (2006) M&A and diversification strategies of VC-backed firms in the biotechnology industry, in: Butler, J. et al. (eds.), Venture capital and the changing world of entrepreneurhip, IAP Greenwich, Connecticut.